Optimal aspirin dose in acute coronary syndromes: an emerging consensus Article

Full Text via DOI: 10.2217/FCA.14.7 PMID: 24762255 Web of Science: 000218616100024

Cited authors

  • DiNicolantonio, James J.; Norgard, Nicholas B.; Meier, Pascal; Lavie, Carl J.; O'Keefe, James H.; Niazi, Asfandyar K.; Chatterjee, Saurav; Packard, Kathleen A.; D'Ascenzo, Fabrizio; Cerrato, Enrico; Biondi-Zoccai, Giuseppe; Bangalore, Sripal; Fuchs, Flavio D.; Serebruany, Victor L.


  • Numerous clinical trials testing the efficacy of aspirin for the secondary prevention of cardiovascular disease have been published. We reviewed the literature pertaining to aspirin dose in acute coronary syndrome patients. Clinical trials assessing the comparative efficacy of different doses of aspirin are scarce. This complex antiplatelet therapy landscape makes it difficult to identify the best aspirin dose for optimizing efficacy and minimizing risk of adverse events, while complying with the various guidelines and recommendations. Despite this fact, current evidence suggests that aspirin doses of 75-100 mg/day may offer the optimal benefit: risk ratio in acute coronary syndrome patients.

Publication date

  • 2014

Published in

International Standard Serial Number (ISSN)

  • 1479-6678

Start page

  • 291

End page

  • 300


  • 10


  • 2